Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 9/20 | 0.40 |
| ▸ | KAT7 | O95251 | 8/20 | 0.40 |
| ▸ | KAT6B | Q8WYB5 | 5/20 | 0.40 |
| ▸ | EDNRB | P24530 | 6/20 | 0.39 |
| ▸ | EDNRA | P25101 | 6/20 | 0.39 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23292514 | 0.84 | TSHR (0.46) | ACLYKAT6AKAT7KAT6BKAT5 | |
| SCHEMBL23292635 | 0.81 | KAT6A (0.45) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL23635954 | 0.81 | BRD4 (0.46) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL23635883 | 0.80 | KDM4E (0.50) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL23631827 | 0.80 | ALDH1A1 (0.51) | MEN1KMT2A | |
| SCHEMBL23635981 | 0.80 | MEN1 (0.39) | KAT6AKAT7KAT6BKAT5KAT8 | |
| SCHEMBL23635956 | 0.79 | MAPT (0.47) | KAT6AKAT7MEN1KMT2ASCN9A | |
| SCHEMBL23631813 | 0.79 | KMT2A (0.47) | KAT6AKAT7KAT6BEDNRBEDNRA | |
| SCHEMBL23631817 | 0.79 | NR3C2 (0.49) | ACLYKAT6AKAT7KAT6BKAT5 | |
| SCHEMBL23292532 | 0.79 | APLNR (0.40) | KAT6AKAT7KAT6BKAT5KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-20210213004-A1 | Compounds | CTXT PTY LTD (AU) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213004-A1 | Compounds | SLC10A1, ABCB11, REN | ACLY 2666/4885KAT6A 951/4885KAT7 490/4885 |
| US-11911372-B2 | Compounds | SLC10A1, ABCB11, REN | ACLY 2666/4885KAT6A 951/4885KAT7 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.